Ig Foundations: Comprehensive Ig Therapy Overview

by | Jan 13, 2026 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: January 13, 2026 Expiration Date: January 13, 2028 Target Audience This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients in need of...
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

Managing Complex Primary Immunodeficiency (PI) Patients

by | Jan 12, 2026 | Uncategorized

Supported by an educational grant from ADMA Biologics Original Release Date: January 13, 2026 Expiration Date: January 13, 2027 Target Audience This activity is intended for pharmacists, nurses, and physicians who treat or may treat patients with a primary...

IgNS 2025 National Conference CE/CME Session Evaluations

by | Jun 23, 2025 | Uncategorized

Thank you for attending the IgNS 2025 National Conference! To receive your CE/CME credits, please complete an evaluation for each session you attended.  For each conference session you attended, click into the corresponding session evaluation.  You will be prompted to...
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

Bronchiectasis in Primary Immunodeficiency

by | May 20, 2025 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: May 23, 2025 Expiration Date: May 23, 2028 Target Audience This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients in need of...
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

Solid Organ Transplantation

by | May 19, 2025 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: May 23, 2025 Expiration Date: May 23, 2028 Target Audience This activity is intended for nurses, pharmacists, and who may use immunoglobulin therapy  in solid organ transplant. Educational Objectives...
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

Transcultural Competency – Much More Than You Think

by | May 19, 2025 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: May 23, 2025 Expiration Date: May 23, 2028 Target Audience This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients in need of...
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

Mast Cell Activation Syndrome

by | May 2, 2025 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: May 23, 2025 Expiration Date: May 23, 2028 Target Audience This activity is intended for nurses, pharmacists, and physicians who treat patients with mast cell activation syndrome.  Educational Objectives...
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

WHIM Syndrome

by | May 2, 2025 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: May 13, 2025 Expiration Date: May 13, 2028 Target Audience This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with WHIM syndrome. ...
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

Dermatology Clinical Update: IVIg for Skin Autoimmunity

by | May 1, 2025 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: May 13, 2025 Expiration Date: May 13, 2028 Target Audience This activity is intended for nurses, pharmacists and physicians who treat patients who may receive Ig therapy to treat skin autoimmunity....
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

Stevens-Johnson Syndrome

by | May 1, 2025 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: May 13, 2025 Expiration Date: May 13, 2028 Target Audience This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with Stevens-Johnson...

Ig Foundations

by | Mar 27, 2025 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: April 30, 2025 Expiration Date: April 30, 2028 Target Audience This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients in need of...
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

GI Complications in the PI Patient

by | Feb 6, 2025 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: February 17, 2025 Expiration Date: February 17, 2028 Target Audience This activity is intended for pharmacists, nurses, and physicians who care for patients with gastrointestinal complications....
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

Clinical Trials: The Basics of Clinical Research

by | Jan 25, 2025 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: February 17, 2025 Expiration Date: February 17, 2028 Target Audience This activity is intended for pharmacists, nurses, and physicians who treat patients that may be interested in clinical trials....
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

Recognizing and Reporting Adverse Drug Reactions in Ig Therapy

by | Jan 25, 2025 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: February 17, 2025 Expiration Date: February 17, 2028 Target Audience This activity is intended for pharmacists, nurses, and physicians who care for patients with potential adverse reactions/side effects....
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

Peripheral Neuropathies and Foot Care

by | Jan 24, 2025 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: February 17, 2025 Expiration Date: February 17, 2028 Target Audience This activity is intended for pharmacists, nurses, and physicians who care for patients with peripheral neuropathies. Educational...
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

Biologics and Biosimilars: Understanding the Differences

by | Jan 23, 2025 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: February 17, 2025 Expiration Date: February 17, 2028 Target Audience This activity is intended for pharmacists, nurses, and physicians who interested in the use of biologics and biosimilars in clinical...
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

Infusion Medication Safety & Clinical Training

by | Sep 12, 2024 | Uncategorized

Speakers: Chuck DiTrapano, RPh & Steven Nice  In this webinar, participants are introduced to RxToolKit, an innovative software designed to streamline and improve medication management, clinical training, and patient safety. The session begins with a brief history...

Understanding Stiff Person Syndrome

by | Jul 11, 2024 | Uncategorized

Provided by the Ig National Society, Inc. Original Release Date: March 20, 2025 Expiration Date: March 20, 2028 Target Audience This activity is intended for nurses, pharmacists, and physicians who care for patients with stiff person syndrome. Educational Objectives...
Updates on the FcRn Inhibitor Therapy in the Management of CIDP

Childhood Post-Infectious Autoimmune Encephalopathy

by | May 3, 2024 | Uncategorized

Childhood Post-Infectious Autoimmune Encephalopathy Provided by the Ig National Society, Inc. Original Release Date: April 14, 2025 Expiration Date: April 14, 2028 Target Audience This activity is intended for nurses, pharmacists, and physicians who care for childhood...
Part 6. Secondary Immune Deficiencies from Biological Agents

Part 6. Secondary Immune Deficiencies from Biological Agents

by | Sep 14, 2021 | Uncategorized

Mark Ballow, MD Professor of PediatricsUniversity of South Florida Supported by Educational Grants from Pfizer and Takeda Speaker Additional Sessions Mark Ballow, MD Professor of PediatricsUniversity of South FloridaSupported by educational grants from: Pfizer, Inc...
Part 5. Immune Dysregulation

Part 5. Immune Dysregulation

by | Sep 14, 2021 | Uncategorized

Jennifer Leiding, MD Director, Multidisciplinary Immunology Services University of South Florida Supported by Educational Grants from Pfizer, Inc and Takeda Speaker Additional Sessions Jennifer Leiding, MD Director, Multidisciplinary Immunology ServicesUniversity of...
Part 4. Pulmonary Complications of Primary Immunodeficiency

Part 4. Pulmonary Complications of Primary Immunodeficiency

by | Sep 14, 2021 | Uncategorized

PJ Maglione, MD, PhD Assistant Professor Boston University School of Medicine Supported by Educational Grants from Pfizer and Takeda Speaker Additional Sessions PJ Maglione, MD, PhD Assistant Professor Boston University School of MedicineSupported by educational...
Part 3. The Complex Primary Immunodeficient Patient

Part 3. The Complex Primary Immunodeficient Patient

by | Sep 14, 2021 | Uncategorized

Richard Wasserman, MD, PhD Medical Director of Pediatric Allergy and ImmunologyMedical City Children’s Hospital Supported by Educational Grantsfrom Pfizer and Takeda Speaker Additional Sessions Richard Wasserman, MD, PhD Medical Director of Pediatric Allergy and...
Part 2. Autoinflammatory Disorders

Part 2. Autoinflammatory Disorders

by | Sep 14, 2021 | Uncategorized

Lori Broderick, MD, PhD Assistant Professor of Pediatrics University of California in San Diego Supported by Educational Grants from Pfizer and Takeda Speaker Additional Sessions Lori Broderick, MD, PhD Assistant Professor of Pediatrics University of California in San...
Part 1. Primary Immunodeficiency: An Overview

Part 1. Primary Immunodeficiency: An Overview

by | Feb 17, 2021 | Uncategorized

Ken Paris, MD, MPH Program DirectorLSU Allergy/Immunology Fellowship Supported by Educational Grants from Pfizer and Takeda Speaker Additional Sessions Ken Paris, MD, MPH Program Director LSU Allergy/Immunology FellowshipSupported by educational grants from: Pfizer,...